Global Search | Novartis

Sort by

Relevance

Newest first

Oldest first

Hide Filters

Showing 2773 results

Clinical Trials / Jul 30, 2025

Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Patients With Uncomplicated Plasmodium Falciparum Malaria
Clinical Trials / Feb 20, 2026

A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN)
Clinical Trials / Mar 11, 2026

Secukinumab Open Label Roll-over Extension Protocol
Clinical Trials / Mar 03, 2026

Safety and Efficacy Study of Fingolimod in Taiwanese Adults (≥ 20years) With Relapsing Remitting Multiple Sclerosis
Clinical Trials / Jun 29, 2025

24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up
Clinical Trials / Mar 18, 2026

Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis
Press release / Dec 09, 2025

1 in 4 metastatic breast cancer patients treated with Novartis Kisqali® remain progression-free beyond 4 years

Progression-free response stayed consistent across age, BMI, and menopausal status in MONALEESA pooled analysis1 KISQALI is only CDK4/6i to demonstrate statistically significant overall survival (OS…
Press release / Jan 09, 2026

Novartis to add radioligand therapy manufacturing facility in Winter Park, Florida, fourth in US to serve patients and advance $23 billion investment

New 35,000-square-foot facility in Winter Park will expand RLT manufacturing footprint to optimize delivery for patients across southeastern USPurpose-built facility will strengthen Novartis RLT…
Press release / Oct 29, 2025

Novartis ianalumab first drug to reduce disease activity and patient burden in Sjögren’s disease Phase III trials

NEPTUNUS-1 and NEPTUNUS-2 achieved primary objective of reduced disease activity and provided clinically meaningful benefit1 Data showed consistent improvements across secondary…
Clinical Trials / Jan 31, 2025

Registry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA)

‹ Previous page
1
…
14
15
16
17
18
19
20
…
278
› Next page